Importantly, a majority of the relapsed patients exhibited an ADAMTS13 activity level below 10% at the time of discontinuing Caplacizumab, underscoring the fact that Caplacizumab does not specifically target the underlying pathophysiology responsible for triggering TTP. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.